Key Takeaways
NewLimit, the longevity startup co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, announced June 2, roughly tripling its valuation to about $3.1 billion.
The company uses epigenetic reprogramming to reset aging cells, and it plans its first human trial, targeting liver disease, in 2027.
The round extends a pattern of crypto-built fortunes moving into frontier science, echoing Tether's recent lead of a $1.4 billion robotics round.
NewLimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, raised a 435 million dollar Series C led by Founders Fund, the company announced June 2, according to STAT News. The round roughly tripled its valuation to about 3.1 billion dollars, up from a mark that sat below 1 billion dollars a year earlier.
Founded in 2021 by Armstrong, bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, NewLimit works on epigenetic reprogramming, which resets the chemical markers that tell genes when to switch on without changing the underlying DNA, as Bitcoin.com News reported. The goal is to make old cells behave like young ones, and Armstrong has put about 110 million dollars of his own money into the company.
The capital moves NewLimit toward the clinic. The company said a prototype reversed the age of old human liver cells, and it plans to begin its first human trial, targeting liver disease, in 2027, per CryptoNews. It remains pre-revenue with no approved product, and its backers now include Thrive Capital, Greenoaks, Kleiner Perkins, and Eli Lilly Ventures.
One detail is worth keeping straight. NewLimit has no blockchain or crypto component, and Armstrong's role there is separate from Coinbase, as CoinAlert News noted. What links it to the wider story is the source of the money, a fortune built in crypto now funding a decade-long bet on biology.
The pattern is getting hard to miss. Earlier this month WYDE covered Tether leading a 1.4 billion dollar round into NEURA Robotics, another case of crypto capital reaching into frontier technology, and the same instinct runs through the payment rails being built for AI agents. Money made moving value on-chain is increasingly chasing the harder problems off it.
People Also Ask
How much did NewLimit raise?
NewLimit raised a 435 million dollar Series C led by Founders Fund, announced June 2, 2026, valuing the company at about 3.1 billion dollars.
Who founded NewLimit?
NewLimit was co-founded in 2021 by Coinbase CEO Brian Armstrong, bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, who serves as its chief executive.
What does NewLimit do?
NewLimit develops epigenetic reprogramming medicines that reset aging cells to a younger state without altering DNA, with a first human trial targeting liver disease planned for 2027.
Is NewLimit a cryptocurrency company?
No. NewLimit is a traditional longevity biotech with no blockchain involvement, although it was co-founded and partly funded by Coinbase CEO Brian Armstrong.